ZYG11B

Summary

ZYG11B (zyg-11 family member B, cell cycle regulator, HGNC:25820) is a protein-coding gene on chromosome 1p32.3, encoding Protein zyg-11 homolog B (Q9C0D3). Serves as substrate adapter subunit in the E3 ubiquitin ligase complex ZYG11B-CUL2-Elongin BC.

Involved in positive regulation of proteasomal ubiquitin-dependent protein catabolic process and protein quality control for misfolded or incompletely synthesized proteins. Part of Cul2-RING ubiquitin ligase complex.

Source: NCBI Gene 79699 — RefSeq curated summary.

At a glance

• Gene–disease (curated): multiple congenital anomalies/dysmorphic syndrome (Limited, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 83 total — 1 likely-pathogenic
• Druggable target: yes
• MANE Select transcript: NM_024646

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25820
Approved symbol	ZYG11B
Name	zyg-11 family member B, cell cycle regulator
Location	1p32.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ13456
Ensembl gene	ENSG00000162378
Ensembl biotype	protein_coding
OMIM	618673
Entrez	79699

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 8 protein_coding

ENST00000294353, ENST00000545132, ENST00000884648, ENST00000884649, ENST00000884650, ENST00000959291, ENST00000959292, ENST00000959293

RefSeq mRNA: 1 — MANE Select: NM_024646 NM_024646

CCDS: CCDS30717

Canonical transcript exons

ENST00000294353 — 14 exons

Exon	Start	End
ENSE00001064564	52816532	52816629
ENSE00001064565	52821439	52827336
ENSE00001141604	52802092	52802139
ENSE00001190651	52801819	52801980
ENSE00001190654	52796734	52796784
ENSE00001190659	52796292	52796391
ENSE00001190664	52790003	52790067
ENSE00001190667	52784877	52785053
ENSE00001190670	52779853	52779993
ENSE00001190674	52771020	52771774
ENSE00001190680	52756458	52756623
ENSE00001935167	52726453	52726683
ENSE00003464514	52813860	52813912
ENSE00003528356	52813536	52813733

Expression profiles

Bgee: expression breadth ubiquitous, 262 present calls, max score 99.13.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.7311 / max 206.8422, expressed in 1808 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
2884	17.6189	1803
2885	3.8548	1461
2883	0.2573	108

Top tissues by expression

264 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
deltoid	UBERON:0001476	99.13	gold quality
vastus lateralis	UBERON:0001379	98.96	gold quality
tibialis anterior	UBERON:0001385	98.79	gold quality
biceps brachii	UBERON:0001507	98.61	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.56	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.44	gold quality
quadriceps femoris	UBERON:0001377	98.38	gold quality
skeletal muscle tissue	UBERON:0001134	97.87	gold quality
cardiac muscle of right atrium	UBERON:0003379	97.84	gold quality
myocardium	UBERON:0002349	97.78	gold quality
left ventricle myocardium	UBERON:0006566	97.77	gold quality
heart right ventricle	UBERON:0002080	97.07	gold quality
middle temporal gyrus	UBERON:0002771	96.91	gold quality
body of tongue	UBERON:0011876	96.56	gold quality
Brodmann (1909) area 46	UBERON:0006483	96.29	gold quality
muscle tissue	UBERON:0002385	96.24	gold quality
lateral nuclear group of thalamus	UBERON:0002736	96.17	gold quality
pons	UBERON:0000988	95.77	gold quality
Brodmann (1909) area 23	UBERON:0013554	95.74	gold quality
kidney epithelium	UBERON:0004819	95.42	gold quality
substantia nigra pars compacta	UBERON:0001965	95.41	gold quality
postcentral gyrus	UBERON:0002581	95.24	gold quality
parietal lobe	UBERON:0001872	95.23	gold quality
entorhinal cortex	UBERON:0002728	94.99	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.79	gold quality
upper arm skin	UBERON:0004263	94.64	gold quality
tongue	UBERON:0001723	94.58	gold quality
superior frontal gyrus	UBERON:0002661	94.46	gold quality
skeletal muscle organ	UBERON:0014892	94.42	gold quality
skin of hip	UBERON:0001554	94.37	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.06

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

268 targeting ZYG11B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-188-3P	100.00	68.76	1240
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4775	99.98	75.00	6394

Literature-anchored findings (GeneRIF, showing 7)

• the ubiquitin ligase CRL2(ZYG-11) redundantly targets the degradation of cyclin B1 in Caenorhabditis elegans and human cells. (PMID:27810909)
• Functional and genetic analyses of ZYG11B provide evidences for its involvement in OAVS. (PMID:32738032)
• ORF10-Cullin-2-ZYG11B complex is not required for SARS-CoV-2 infection. (PMID:33827988)
• Molecular basis for recognition of Gly/N-degrons by CRL2(ZYG11B) and CRL2(ZER1). (PMID:34214466)
• Structural insights into ORF10 recognition by ZYG11B. (PMID:35636250)
• A close shave: How SARS-CoV-2 induces the loss of cilia. (PMID:35695891)
• LncRNA LINC01871 sponging miR-142-3p to modulate ZYG11B promotes the chemoresistance of colorectal cancer cells by inducing autophagy. (PMID:36847071)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	zyg11	ENSDARG00000007737
danio_rerio	zyg11l	ENSDARG00000101799
mus_musculus	Zyg11b	ENSMUSG00000034636
rattus_norvegicus	Zyg11b	ENSRNOG00000010859
caenorhabditis_elegans		WBGENE00006996

Paralogs (2): ZER1 (ENSG00000160445), ZYG11A (ENSG00000203995)

Protein

Protein identifiers

Protein zyg-11 homolog B — Q9C0D3 (reviewed: Q9C0D3)

All UniProt accessions (3): A8DPD7, Q9C0D3, B4DK95

UniProt curated annotations — full annotation on UniProt →

Function. Serves as substrate adapter subunit in the E3 ubiquitin ligase complex ZYG11B-CUL2-Elongin BC. Acts to target substrates bearing N-terminal degrons for proteasomal degradation with the first four residues of substrates being the key recognition elements. Prefers Nt-Gly but also has the capacity to recognize Nt-Ser, -Ala and -Cys. Involved in the clearance of proteolytic fragments generated by caspase cleavage during apoptosis since N-terminal glycine degrons are strongly enriched at caspase cleavage sites. Also important in the quality control of protein N-myristoylation in which N-terminal glycine degrons are conditionally exposed after a failure of N-myristoylation. In addition, plays a role in the amplification of cGAS to enhance innate immune response. Mechanistically, strengthens the processes of cGAS binding with dsDNA and assembling oligomers and also accelerates and stabilizes cGAS-DNA condensation, thereby enhancing production of antiviral IFNs and inflammatory cytokines.

Subunit / interactions. (Microbial infection) Interacts with SARS-COV-2 protein ORF10. Interacts with ELOC/Elongin C. Part of an E3 ubiquitin ligase complex including ZYG11B, CUL2 and Elongin BC.

Subcellular location. Cytoplasm.

Post-translational modifications. (Microbial infection) Ubiquitinated; leading to proteasomal degradation in the presence of herpes simplex virus 1/HHV-1.

Similarity. Belongs to the zyg-11 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9C0D3-1	1	yes
Q9C0D3-2	2

RefSeq proteins (1): NP_078922* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001611	Leu-rich_rpt	Repeat
IPR011989	ARM-like	Homologous_superfamily
IPR016024	ARM-type_fold	Homologous_superfamily
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR051341	Zyg-11_UBL_adapter	Family
IPR055142	ZER1-like_C	Domain
IPR056845	LRR_Zer-1	Domain

Pfam: PF22964, PF25013

UniProt features (31 total): helix 17, mutagenesis site 6, repeat 3, turn 2, chain 1, sequence conflict 1, splice variant 1

Structure

Experimental structures (PDB)

14 structures.

PDB	Method	Resolution (Å)
7EP1	X-RAY DIFFRACTION	1.85
7EP0	X-RAY DIFFRACTION	2.16
7EP2	X-RAY DIFFRACTION	2.38
7XYW	X-RAY DIFFRACTION	2.5
7XYV	X-RAY DIFFRACTION	2.52
7XV7	X-RAY DIFFRACTION	2.6
7XYX	X-RAY DIFFRACTION	2.87
7YC2	X-RAY DIFFRACTION	2.9
9LK6	ELECTRON MICROSCOPY	3.27
9LK2	ELECTRON MICROSCOPY	3.37
9BIE	ELECTRON MICROSCOPY	3.4
9BJ8	ELECTRON MICROSCOPY	3.78
9BID	ELECTRON MICROSCOPY	3.99
9BJ9	ELECTRON MICROSCOPY	4.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9C0D3-F1	92.35	0.85

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (6):

Position	Phenotype
570	complete loss of n-degron binding.
18	abolishes interaction with eloc.
522	complete loss of n-degron binding.
523	complete loss of n-degron binding.
526	complete loss of n-degron binding.
567	complete loss of n-degron binding.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 198 (showing top): WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN, GOBP_REGULATION_OF_PROTEASOMAL_UBIQUITIN_DEPENDENT_PROTEIN_CATABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS, GOBP_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, GOBP_POSITIVE_REGULATION_OF_PROTEOLYSIS, GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS, GOBP_REGULATION_OF_PROTEOLYSIS, GOBP_PROTEIN_CATABOLIC_PROCESS, GOCC_TRANSFERASE_COMPLEX, ZHENG_FOXP3_TARGETS_IN_THYMUS_UP, GOBP_PROTEOLYSIS

GO Biological Process (2): protein quality control for misfolded or incompletely synthesized proteins (GO:0006515), positive regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032436)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): cytoplasm (GO:0005737), Cul2-RING ubiquitin ligase complex (GO:0031462)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein catabolic process	1
regulation of proteasomal ubiquitin-dependent protein catabolic process	1
proteasome-mediated ubiquitin-dependent protein catabolic process	1
positive regulation of proteasomal protein catabolic process	1
positive regulation of ubiquitin-dependent protein catabolic process	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
cullin-RING ubiquitin ligase complex	1

Protein interactions and networks

STRING

670 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZYG11B	CUL2	Q13617	832
ZYG11B	ELOC	Q15369	711
ZYG11B	RBX1	P62877	696
ZYG11B	LRR1	Q96L50	695
ZYG11B	ELOB	Q15370	677
ZYG11B	ZER1	Q7Z7L7	552
ZYG11B	PAEP	P09466	432
ZYG11B	SNX11	Q9Y5W9	415
ZYG11B	NMT1	P30419	402
ZYG11B	KLHDC2	Q9Y2U9	391
ZYG11B	UNC119	Q13432	389
ZYG11B	VHL	P40337	367
ZYG11B	MEX3D	Q86XN8	349
ZYG11B	CUL5	Q93034	342
ZYG11B	PLEKHM3	Q6ZWE6	335

IntAct

161 interactions, top by confidence:

A	B	Type	Score
POLG2	POLG	psi-mi:“MI:0914”(association)	0.950
CUL2	VHL	psi-mi:“MI:0914”(association)	0.940
VIM	NEFL	psi-mi:“MI:0914”(association)	0.840
MTDH	SND1	psi-mi:“MI:0914”(association)	0.840
RGS20	GLRX3	psi-mi:“MI:0914”(association)	0.810
KIF22	KPNA3	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
ZYG11B	CUL2	psi-mi:“MI:0915”(physical association)	0.670
CDCA5	RAD21	psi-mi:“MI:0914”(association)	0.640
ORF10	CUL2	psi-mi:“MI:0914”(association)	0.640
CFTR	HAX1	psi-mi:“MI:0914”(association)	0.610
GBF1	ZYG11B	psi-mi:“MI:0915”(physical association)	0.560
OPTN	ZYG11B	psi-mi:“MI:0915”(physical association)	0.560
OS9	AGRN	psi-mi:“MI:0914”(association)	0.530
AP3S1	AP3B1	psi-mi:“MI:0914”(association)	0.530
TAFA4	NRP1	psi-mi:“MI:0914”(association)	0.530
MCAT	ALAS1	psi-mi:“MI:0914”(association)	0.530
WFDC9	CTSC	psi-mi:“MI:0914”(association)	0.530
ORF10	PPT1	psi-mi:“MI:0914”(association)	0.530
CLEC11A	VWA8	psi-mi:“MI:0914”(association)	0.530
GRK7	HSP90AA1	psi-mi:“MI:0914”(association)	0.530
SLAIN1	HSPA9	psi-mi:“MI:0914”(association)	0.530
CLPSL1	TNFAIP1	psi-mi:“MI:0914”(association)	0.530

BioGRID (157): ZYG11B (Affinity Capture-MS), ZYG11B (Affinity Capture-MS), ZYG11B (Affinity Capture-MS), ZYG11B (Affinity Capture-MS), ZYG11B (Affinity Capture-MS), ZYG11B (Affinity Capture-MS), ZYG11B (Affinity Capture-MS), ZYG11B (Affinity Capture-MS), ZYG11B (Affinity Capture-MS), ZYG11B (Affinity Capture-MS), ZYG11B (Affinity Capture-MS), ZYG11B (Affinity Capture-MS), ZYG11B (Affinity Capture-MS), ZYG11B (Affinity Capture-MS), ZYG11B (Affinity Capture-MS)

ESM2 similar proteins: A0A3L7I2I8, A0JMZ3, A5HK05, A7MB89, A7YWD2, O60733, O75031, O94829, O94955, P0C7A6, P42694, P49754, P97570, P97819, Q05AL1, Q1LVW0, Q29RM5, Q2KI54, Q2T9K6, Q3UFS0, Q3UJZ3, Q4V890, Q5KU39, Q5R6S3, Q5R974, Q5T9G4, Q5TYQ1, Q5VZK9, Q68FK4, Q6DFV5, Q6EDY6, Q6NYU2, Q6QI06, Q6R327, Q7T3P8, Q8C0T1, Q8CEF1, Q8IUR7, Q8NFZ0, Q91W86

Diamond homologs: A0JMZ3, A2BFL2, P21541, Q3UFS0, Q5RAG3, Q5TYQ1, Q6WRX3, Q7Z7L7, Q80ZJ6, Q9C0D3

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 203 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Chaperone Mediated Autophagy	6	23.8×	1e-04
Antigen Presentation: Folding, assembly and peptide loading of class I MHC	5	15.8×	4e-03
Neddylation	12	4.5×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

83 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	53
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1691311	NM_024646.3(ZYG11B):c.628C>T (p.Arg210Ter)	Likely pathogenic

SpliceAI

2274 predictions. Top by Δscore:

Variant	Effect	Δscore
1:52726689:G:GT	donor_gain	1.0000
1:52756436:A:AG	acceptor_gain	1.0000
1:52756437:T:G	acceptor_gain	1.0000
1:52756438:A:AG	acceptor_gain	1.0000
1:52756447:T:A	acceptor_gain	1.0000
1:52756448:G:A	acceptor_gain	1.0000
1:52756584:G:GT	donor_gain	1.0000
1:52771016:ACAG:A	acceptor_loss	1.0000
1:52771017:CAGGT:C	acceptor_loss	1.0000
1:52771018:AGGTC:A	acceptor_loss	1.0000
1:52771019:G:A	acceptor_loss	1.0000
1:52779847:TCACA:T	acceptor_loss	1.0000
1:52779848:CACA:C	acceptor_loss	1.0000
1:52779850:CA:C	acceptor_loss	1.0000
1:52779851:A:AC	acceptor_loss	1.0000
1:52779852:GGT:G	acceptor_gain	1.0000
1:52779989:TAAAG:T	donor_loss	1.0000
1:52779990:AAAG:A	donor_loss	1.0000
1:52779991:AAGGT:A	donor_loss	1.0000
1:52779992:AGG:A	donor_loss	1.0000
1:52779994:GT:G	donor_loss	1.0000
1:52779995:T:G	donor_loss	1.0000
1:52784873:CCA:C	acceptor_loss	1.0000
1:52784874:CA:C	acceptor_loss	1.0000
1:52784875:A:AG	acceptor_gain	1.0000
1:52784876:G:GC	acceptor_gain	1.0000
1:52784876:GC:G	acceptor_gain	1.0000
1:52784876:GCTT:G	acceptor_gain	1.0000
1:52785050:GCAG:G	donor_gain	1.0000
1:52785051:CAGG:C	donor_loss	1.0000

AlphaMissense

4920 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:52771647:G:A	G275E	1.000
1:52771709:T:C	F296L	1.000
1:52771711:T:A	F296L	1.000
1:52771711:T:G	F296L	1.000
1:52779860:G:A	G320E	1.000
1:52779944:T:C	L348P	1.000
1:52779946:T:C	F349L	1.000
1:52779948:T:A	F349L	1.000
1:52779948:T:G	F349L	1.000
1:52784926:T:C	L381P	1.000
1:52784929:C:A	A382D	1.000
1:52784931:G:C	A383P	1.000
1:52784934:A:C	S384R	1.000
1:52784936:C:A	S384R	1.000
1:52784936:C:G	S384R	1.000
1:52784938:C:A	A385D	1.000
1:52784940:T:C	C386R	1.000
1:52784941:G:A	C386Y	1.000
1:52784942:T:G	C386W	1.000
1:52784946:T:C	F388L	1.000
1:52784948:T:A	F388L	1.000
1:52784948:T:G	F388L	1.000
1:52784951:C:A	N389K	1.000
1:52784951:C:G	N389K	1.000
1:52790004:T:C	L424S	1.000
1:52790009:A:G	K426E	1.000
1:52790011:G:C	K426N	1.000
1:52790011:G:T	K426N	1.000
1:52790012:A:G	N427D	1.000
1:52790013:A:C	N427T	1.000

dbSNP variants (sampled 300 via entrez): RS1000060559 (1:52779390 T>C), RS1000077170 (1:52824077 C>A,T), RS1000095681 (1:52816788 T>C), RS1000101320 (1:52727557 A>G), RS1000102763 (1:52813006 G>A,C), RS1000142476 (1:52730800 A>G), RS1000166375 (1:52803486 A>G,T), RS1000174065 (1:52730520 G>T), RS1000197254 (1:52774054 G>A), RS1000223216 (1:52810039 A>C,G), RS1000274462 (1:52730248 G>A,C), RS1000276962 (1:52809754 CTGA>C), RS1000310815 (1:52817221 T>G), RS1000336279 (1:52810995 T>C), RS1000360286 (1:52767239 T>G)

Disease associations

OMIM: gene MIM:618673 | disease phenotypes: MIM:164210

GenCC curated gene-disease

Disease	Classification	Inheritance
multiple congenital anomalies/dysmorphic syndrome	Limited	Autosomal dominant

Mondo (2): craniofacial microsomia 1 (MONDO:0958175), multiple congenital anomalies/dysmorphic syndrome (MONDO:0019042)

Orphanet (1): Goldenhar syndrome (Orphanet:374)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90002394_137	Monocyte percentage of white cells	2.000000e-12

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007989	monocyte percentage of leukocytes

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL6066862 (PROTEIN-PROTEIN INTERACTION), CHEMBL6193837 (PROTEIN-PROTEIN INTERACTION)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression, increases expression	3
bisphenol S	increases methylation, affects cotreatment, decreases expression	2
Benzo(a)pyrene	affects methylation, decreases methylation	2
Valproic Acid	affects expression, decreases expression	2
Cyclosporine	decreases expression	2
aristolochic acid I	decreases expression	1
bisphenol A	increases expression	1
salinomycin	decreases expression	1
arsenite	affects binding, decreases reaction	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	increases methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
tanespimycin	increases expression, affects cotreatment	1
14-deoxy-11,12-didehydroandrographolide	increases expression	1
abrine	decreases expression	1
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide	increases expression	1
STA 9090	increases expression	1
VER 155008	increases expression, affects cotreatment	1
(+)-JQ1 compound	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Norethindrone Acetate	affects cotreatment, decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants	increases abundance, decreases expression	1
Carbamazepine	affects expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Estradiol	decreases expression, affects cotreatment	1

ChEMBL screening assays

12 unique, capped per target: 12 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5554710	Binding	PROTAC (AATac) activity at ZYG11B/ZER1/EML4-ALK in human NCI-H3122 cells assessed as protein degradation upto 20 uM incubated for 72 hrs by immunoblot analysis	Distinct Amino Acid-Based PROTACs Target Oncogenic Kinases for Degradation in Non-Small Cell Lung Cancer (NSCLC). — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.